A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders

NCT04739423 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia

Interventions

DRUG: clenbuterol (CST-103), nadolol (CST-107), matching placebo

Sponsor

CuraSen Therapeutics, Inc.